Background {#Sec1}
==========

Breast cancer, the most common cancer in women, is highly heterogeneous with various clinical courses and outcomes. Adjuvant systemic therapies, including chemotherapy, hormonal treatment, and anti-HER2 (human epidermal receptor) agents have been proven to reduce disease recurrence and prolong survival. Breast cancers are classified into genomically defined subgroups, including four major intrinsic subtypes: luminal A, luminal B, HER2^+^, and triple-negative (TN) tumors. Clinical courses, patterns of metastasis, and prognosis vary among these subgroups. Although most relapses occur during the first 5 years after diagnosis, late recurrence has been reported, especially in luminal breast cancer.

Unlike most solid malignancies, breast cancer may recur 5--10 years after initial treatment. Previous studies reported that high-bulk disease, high proliferative index, and HER2-positive malignancies corresponded to recurrence earlier than 10 years, whereas progesterone receptor-positive (PR^+^) disease was associated with relapse later than 10 years \[[@CR1], [@CR2]\]. Follow-up visits are usually scheduled annually for patients who have had five disease-free years or who have completed hormonal treatment. Some patients develop rapid and extensive metastasis during the follow-up intervals; a few of these patients cannot undergo chemotherapy owing to organ dysfunction or lower performance status as a result of widespread metastasis.

Although adjuvant chemotherapy reduces the risk of recurrence in the first 5 years \[[@CR3]\], its effect beyond 5 years is unknown. Patients with estrogen receptor-positive (ER^+^) breast cancer benefit from adjuvant tamoxifen, with the greatest benefit in the first 4 years \[[@CR4]\] and an additional carry-over reduction of recurrence risk for more than 5 years. Use of tamoxifen extended to 10 years in women with early-stage breast cancer reportedly reduces the risk of late recurrence \[[@CR5]\]. Despite the substantial benefit of the 10-year tamoxifen regimen, higher incidence of toxicity, including endometrium cancer and thromboembolism, has also been shown. To improve risks and benefits, patients with high chances of late relapse might be better candidates for such long-term treatment.

The objective of this study was to identify predictors of relapse later than 5 years in early breast cancer. Secondary objectives were identification of predictors of late recurrence specifically in luminal breast cancer, patterns of recurrence, and changes in biomarkers by the time of recurrence. Predicting patients with high chances of late relapse may modify individual follow-up schedules and individualize long-term hormonal treatment in the right patients.

Methods {#Sec2}
=======

All patients who had histologically confirmed breast cancers that recurred after initial treatment were retrospectively reviewed. Patients with incomplete biomarker data were excluded. Data from all patients with recurrent breast cancer were recorded, including demographic, initial stage and tumor biomarkers, date and site of recurrence, any change in biomarkers, and time to progression after first relapse.

Tumors were defined as positive for ER or PR if more than 1 % of cells expressed ER or PR (respectively) \[[@CR6]\]. Tumors were considered HER2^+^ if they scored 3+ by immunohistochemistry; or if the ratio of HER2-neu and centromere of 17th chromosome was greater than 2 \[[@CR7]\].

For our secondary objectives regarding predictors of late relapse in luminal tumors, we decided to use ER titer as a possible predictive marker. Low ER titer was defined as less than 50 % of tumor cells expressing ER immunohistochemically \[[@CR8]\].

All enrolled patients were divided into two groups; those whose relapses were within the first 5 years, and later than 5 years from initial treatment, were respectively grouped as the early recurrence and late recurrence groups. Clinical, pathological, and biomarker data were analyzed for factors that predicted late recurrence in all patients, and in those with luminal tumors. Patterns of relapse and changes of biomarkers over time were also evaluated. The study was approved by Siriraj Institutional Review Board (Protocol number 204/2557(EC1)).

Statistical analysis {#Sec3}
--------------------

Associations between clinicopathological parameters, immunohistological markers, and late recurrence were assessed using the chi-square and Fisher exact test. Multivariate analysis included only those variables that were positive in univariate analysis and were assessed using multiple binary logistic regression analysis. Also, binary logistic regression was used to evaluate patterns of metastasis in different tumor subtypes. *p* values were two-sided; all confidence intervals were at 95 %. Survival curves were estimated using Kaplan--Meier curves. Analyses were performed using SPSS version 20. This study was approved by the Siriraj Institution Review Board.

Results {#Sec4}
=======

We initially found 554 breast cancer patients who suffered relapses during 2005--2013 using the International Classification of Disease and related health problem 10th revision (ICD10) codes for metastatic breast cancer. After excluding patients with metastatic disease at the first diagnosis, who had incomplete data, or who had refused surgery, 300 patients were eligible for analysis. Their median age was 48 years old. Most of the patients (75 %) were premenopausal at the time of first diagnosis. Their median time to first recurrence was 45.4 months (range: 4.4--250 months). For all patients whose disease had recurred, 78 and 90 % developed recurrence within 10 and 15 years, respectively. Almost all patients received adjuvant systemic treatment and radiotherapy as their physician recommended; only 4 % rejected at least one recommended therapy. Of patients for whom chemotherapy was indicated, 60 % received anthracycline-based chemotherapy and 19 % had combined methotrexate, 5FU, and oral cyclophosphamide. Previously, most patients had received tamoxifen as an adjuvant hormonal therapy.

We divided patients into two groups, early recurrence (within 5 years after diagnosis; *n* = 180; 60 %) and late recurrence (later than 5 years; *n* = 120; 40 %). There was no difference in both early and late recurrence rates among patients who underwent mastectomy and breast-conserving surgery. Among node-positive patients, 70 % were in the early group and 43 % were in the late group (*p* \< 0.001). Patients with tumors larger than 2 cm experienced more frequent early recurrence (78 % early group vs 57 % later group). Subtypes of breast cancer also predicted recurrence time. Most of the late group had luminal tumors (85 %) followed by TN tumor (11 %). Among 65 HER2^+^ patients, only 5 (4.2 %) experienced late recurrence, as did only 1.6 % of patients with ER^−^/PR^−^/HER2^+^ tumors (Table [1](#Tab1){ref-type="table"}).Table 1Patients' characteristics by time to diagnosis of breast cancer recurrenceTime to recurrenceTotal (*n* = 300)*p*\<5 years (*n* = 180)≥5 years (*n* = 120)Mean age, years (SD)48.45 (10.59)49.17 (10.61)3000.562Menopausal statusPre/peri-menopause138 (76.6)83 (69.1)2210.628Postmenopause42 (23.4)37 (30.9)79T stage≤2 cm40 (22.2)51 (42.5)91\<0.001\>2 cm140 (77.8)69 (57.5)209N stageNode-negative53 (29.4)69 (56.6)122\<0.001Node + 1-3 nodes56 (31.1)36 (30)92Node + 4-9 nodes39 (21.7)12 (10)51Node+ ≥ 10 nodes32 (17.8)3 (2.5)35N stageNode-negative53 (29.4)69 (56.6)121\<0.001Node-positive127 (70.6)51 (43.4)179Grade (*n* = 262)113 (7.6)19 (20.6)320.0022103 (60.5)56 (60.8)159354 (31.9)17 (18.6)71LVI (*n* = 262)Yes108 (63.9)43 (46.2)1510.006No61 (36.1)50 (53.8)111ERPositive101 (56.1)104 (86.6)2050.001Negative79 (43.9)16 (13.4)95PRPositive76 (42.2)95 (79.1)1710.001Negative104 (57.8)25 (20.9)129HER2Positive60 (33.3)5 (4.1)650.001Negative120 (66.7)115 (95.9)235SubtypesLuminal A/B/HER2^−^76 (42.2)102 (85.0)1780.001Triple-negative44 (24.4)13 (10.8)57HER235 (19.4)2 (1.6)37ER^+^ or PR^+^ and HER2^+^25 (14.0)3 (2.6)28Surgery (*n* = 293)Mastectomy163 (90.5)106 (88.3)2690.31Breast-conserving12 (6.7)12 (10)24Adjuvant systemic treatmentNone8 (4.4)4 (3.3)120.001Chemotherapy81 (45.0)20 (16.6)101Endocrine therapy17 (9.4)35 (29.1)52Chemo-endocrine74 (41.2)61 (51.0)135Adjuvant RTYes108 (60.0)47 (39.1)1550.073

Most patients with tumors larger than 2 cm or lymph node metastasis relapsed early, while higher proportion of patients with small tumors or negative lymph nodes were found among patients who experienced late recurrence (Table [2](#Tab2){ref-type="table"}). In multivariate analysis, factors that predicted late recurrence were ER^+^, PR^+^ status, and HER2^−^status, whereas HER2^+^ status predicted early relapse (Table [2](#Tab2){ref-type="table"}).Table 2Univariate and multivariate analyses of factors correlated with late recurrence (≥5 years)FactorsUnivariate analysisMultivariate analysisRR/CI*p*RR/CI*p*T stage≤2 cm2.59/1.57--4.28\<0.0012.09/1.09--3.990.026\>2 cm11N stage−3.24/2.0--5.260.137+1Grade11120.39/0.18--0.850.0170.39/0.15--0.970.04330.24/0.1--0.580.0010.46/0.17--1.30.142LVI+0.49/0.29--0.810.0060.82/0.44--1.550.546−11ER+5.08/2.78--9.29\<0.0013.25/1.1--9.60.033−1PR+5.20/3.06--8.84\<0.0011.86/0.75--4.620.184−11HER2+0.09/2.35--29.3\<0.0010.12/0.03--0.430.001−11*RR* relative risk, *CI* 95 % confidence interval, *LVI* lymphovascular invasion

Because luminal tumors had a substantial chance of late recurrence, we investigated factors that predict late relapse in this specific population. Among the enrolled 300 patients, 206 (68.7 %) had ER^+^ and/or PR^+^ tumors. Of 206 patients with luminal tumor, 105 (50.9 %) experienced late recurrence; as with the overall population, early recurrence occurred in luminal tumor patients with larger tumor, positive lymph nodes, and *HER2* amplification (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Two out of 74 late-relapse patients (2.8 %) had low ER titers, and 15 out of 92 patients with early relapse (18 %) had low ER (*p* = 0.002). Patients with low ER titers or whose tumors were ER^−^ or PR^−^ had significantly less late relapse (Table [3](#Tab3){ref-type="table"}). Multivariate analysis associated highly positive ER intensity with late recurrence (Table [4](#Tab4){ref-type="table"}).Table 3Patient characteristics by time to diagnosis of recurrence of breast cancer in luminal subgroupTime to recurrenceTotal (*n* = 206)*p*\<5 years (*n* = 101)≥5 years (*n* = 105)Mean age, years (SD)49.17 (10.5)48.45 (10.6)2060.562Menopausal statusPre/peri-menopause74 (73.2)71 (67.6)1450.377Postmenopause27 (26.8)34 (32.4)61T stage≤2 cm19 (18.9)42 (40.0)610.001\>2 cm82 (81.1)63 (60.0)145N stageNode-negative29 (28.7)59 (56.2)88\<0.001Node-positive72 (71.3)46 (43.8)118Grade (*n* = 174)19 (9.4)15 (18.9)240.019259 (62.1)51 (64.5)110327 (28.5)13 (16.6)40Lymphovascular invasion (*n* = 176)Yes59 (62.1)42 (51.8)1010.172No36 (37.9)39 (48.2)75ER titer (*n* = 156)High (≥50 %)67 (81.7)72 (97.2)1390.002Low (\<50 %)15 (18.3)2 (2.8)17ER^−^ or PR^−^26 (25.7)4 (3.8)30\<0.001HER2^+^25 (24.7)3 (2.8)28\<0.001Adjuvant therapyNone4 (3.9)2 (1.9)60.047Chemotherapy7 (6.9)7 (6.6)14Endocrine therapy17 (16.8)35 (33.3)52Chemo-endocrine73 (72.4)61 (58.2)154Table 4Univariate and multivariate analyses of recurrence later than 5 years in patients with luminal tumorsFactorsCategoryLater than 5 yearsUnivariate analysisMultivariate analysis/total *n*RR/CI*p*RR/CI*p*T stage≤2 cm45/653.04/1.63--5.67\<0.0013.96/1.66--9.430.002\>2 cm60/14111N stageNode^−^60/893.31/1.86--5.91\<0.0013.47/1.51--7.990.003Node^+^45/11711Grade115/2311253/1150.46/0.18--1.160.0990.15/0.04--0.620.008314/410.28/0.10--0.810.0190.23/0.05--1.050.057ER titerHigh ≥ 50 %72/1398.06/1.78--36.570.00710.4/1.88--57.50.007Low \< 50 %2/1711ER^−^ or PR^−^Yes101/1768.75/2.93--26.15\<0.0012.95/0.12--74.60.511No4/3011HER2Positive3/280.09/0.03--0.31\<0.0010.44/0.01--16.90.655Negative102/17811*RR* relative risk, *CI* 95 % confidence interval

The different breast cancer subtypes showed different times to disease progression. As expected, the luminal/HER2^−^ subgroup had the longest disease-free survival (DFS; median DFS: 65.95 months), whereas patients with TN or ER^−^/HER2^+^ disease had worse prognoses (median DFS: 23.7 and 24.4 months, respectively; Fig. [1](#Fig1){ref-type="fig"}). However, at that time, 92.2 % of HER2^+^ patients received no adjuvant trastuzumab owing to reimbursement issues and financial constraints.Fig. 1Cumulative incidence of first relapse of breast cancer by breast cancer subtype

Liver and brain were the most common metastasis sites for patients with early relapse. However, lung or soft tissue and bone metastasis occurred throughout the follow-up period. Patients with locoregional recurrence as first relapse site experienced longer DFS (median: 82.55 months; range: 7.17--234.9 months) compared with those with distant metastasis (median DFS: 42.58 months; range: 4.40--250.27 months). In the overall population, metastasis to the central nervous system was largely found in patients with TN and HER2^+^ cancers. Luminal HER2^−^ tumors were predominantly metastasized to the bone and were less likely to spread to the liver at first relapse (Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}). Patterns of relapse did not significantly differ between luminal patients who relapsed late or early (Table [7](#Tab7){ref-type="table"}). The late-relapse group had longer median time to disease progression (15.16 months) than did the early group (8.16 months; *p* = 0.008) (Fig. [2](#Fig2){ref-type="fig"}).Table 5Metastasis patterns according to the time to diagnosis of breast cancer recurrenceSite of recurrencesTime to recurrenceTotal (*n* = 300)*p*\<5 years (*n* = 180)≥5 years (*n* = 120)Pulmonary metastasis132 (73.3)91 (75.8)2230.102Bone metastasis82 (45.5)58 (48)1401.051Brain metastasis22 (12.2)4 (3.3)260.007Liver metastasis57 (31.6)20 (16.6)770.004LN metastasis38 (21.1)29 (24.1)670.534Skin metastasis32 (17.7)22 (18.3)540.902Locoregional recurrence10 (5.0)16 (8.0)260.019Distant metastasis170 (94.4)104 (86.6)2740.088Multiple site metastasis132 (73.3)76 (63.3)2080.066Table 6Relative risk for site of first recurrence by breast cancer subtype in 300 womenSiteTNBC (*n* = 57)HER2 (*n* = 37)ER/PR/HER2 (*n* = 28)ER/PR (*n* = 178)RR/CI*p*RR/CI*p*RR/CI*p*RR/CI*p*Lung0.959/0.49--1.840.9010.655/0.36--1.190.1660.495/0.22--1.110.0831.399/0.82--2.350.207Bone0.554/0.30--1.000.0520.708/0.40--0.230.2231.159/0.53--2.520.7101.849/1.15--2.950.010Brain2.493/1.04--5.920.0342.489/1.07--5.780.0303.436/1.25--9.440.0240.222/0.09--0.54\<0.001Liver1.439/0.76--2.700.2564.897/2.71--8.82\<0.0011.70/0.74--3.860.2010.220/0.12--0.38\<0.001LN1.641/0.85--3.130.1312.160/1.17--3.960.0121.748/0.75--4.060.1910.397/0.22--0.690.001Skin1.112/0.53--2.320.7770.577/0.25--1.290.1770.740/0.24--2.220.5511.327/0.71--2.450.365*CI* 95 % confidence interval, *RR* relative risk, *TNBC* triple-negative breast cancerTable 7Metastasis patterns in patients with luminal subtypes according to the time to diagnosis of breast cancer recurrenceSite of first recurrenceTime to recurrenceTotal (*n* = 206)*p*\<5 years (*n* = 101)≥5 years (*n* = 105)Pulmonary metastasis71 (70.2)83 (79.0)1540.150Bone metastasis58 (57.4)50 (47.6)1080.160Brain metastasis9 (8.9)4 (3.8)130.134Liver metastasis20 (19.8)15 (14.2)350.294LN metastasis13 (12.8)24 (22.8)370.062Skin metastasis20 (19.8)19 (18.0)390.756Fig. 2Progression-free survival after first relapse categorized by early or late recurrence (months)

Eighty of the 300 patients were re-biopsied at the time of recurrence. Most (79 %) had biomarkers similar to those seen at their initial diagnoses. Discordant biomarkers were infrequent and did not significantly differ by relapse time (Table [8](#Tab8){ref-type="table"}).Table 8Discordance of hormonal receptor and HER2 status between primary and metastatic samples (only in patients with rebiopsies and with diagnoses confirmed by pathologist; *n* = 80)Change of HR and/or HER2 statusEarly recurrence (*n* = 40)Late recurrence (*n* = 40)No change ER status3636ER changePos → neg22Neg → pos22No change PR status3537PR changePos → neg22Neg → pos31No change HER2 status3538HER2 changePos → neg10Neg → pos42Changes were seen in 17 patients (some patients had more than 1 biomarker changed)

Discussion {#Sec5}
==========

As with most solid cancers, breast cancer relapse rates are highest in the first 5 years following initial treatment and decline to a steady state after 7--8 years. Late relapse of breast cancer is occasionally found after DFS of 5--10 years. Breast cancer patients who had high disease bulk (such as large tumors or positive lymph nodes) generally had higher chances of both early and late recurrence \[[@CR1]\]. A previous study showed that recurrence that occurred later than 10 years was associated with positive lymph node or PR^+^ disease \[[@CR2]\].

Our study confirmed that tumor size and regional lymph node involvement were predictive of early recurrence. In addition, biomarkers were stronger predictors of early or late recurrence. HER2^+^ status predicted recurrence within 5 years; only five HER2^+^ patients (4 %) were in the late group, and three of these five also had positive hormone receptors. Because TN breast cancer is known to be an especially aggressive subtype, our study showed cancers of this subtype made up 10 % of the late group, compared with 24 % of the early group. These patterns have implications for follow-up scheduling in patients whose DFS has been longer than 5 years; HER2^+^ patients can be set for annual visits, whereas ER^+^ patients (especially those who had high ER titer) might need more frequent follow-up visits because the risk of recurrence is still retained.

Patients with hormone receptor-positive breast cancer remain at risk of recurrence for as long as they survive. For that reason, many investigators have explored the benefit of extended therapy beyond the standard treatment of 5 years. Recently, several studies showed that extended tamoxifen reduces late recurrence risk by one third compared with no further hormonal therapy beyond 5 years \[[@CR5], [@CR9]\]. Extended use of aromatase inhibitors has also been shown to reduce the risk of late relapse by nearly 50 % compared with no further treatment \[[@CR10], [@CR11]\]. However, prolonged endocrine therapy leads to adverse events (such as hot flashes, sexual dysfunction, uterine bleeding, or osteoporosis) in approximately half of patients who take it. Therefore, treating only patients with a clear chance of recurrence but not those unlikely to develop late recurrence is a reasonable practice. The question is: Which patient has risk of late relapse and will benefit from extended hormonal therapy?

We therefore explored more patients with luminal tumors. Identifying patients with high risk of late relapse and who may benefit from extended hormonal therapy for up to 10 years could aid in treatment decisions. In luminal tumors, titers of ER and HER2 predicted late relapse. Patients with ER titers \<50 % or concomitant HER2^+^ disease experienced significantly lower rates of late recurrence. Therefore, benefits of extended hormonal treatment in these patients might not outweigh the risk of treatment. Given that coexpression of ER and PR were related to late recurrence compared with patients who had only ER or PR, our findings support greater benefit of extended letrozole treatment in patients who had ER^+^/PR^+^ tumors, as shown in subsequent analysis of MA17 \[[@CR12]\].

Recently, studies using multi-parameter assays, for example the 12-gene EndoPredict, Breast Cancer Index (BCI), or 50 gene *PAM50 ROR*, investigated the risk of late recurrence \[[@CR13], [@CR14]\]. These molecular assays can separate patients with low risk of developing recurrence at 5--10 years or 10--15 years \[[@CR15]\]. Among these parameters, *PAM50 ROR* was the strongest molecular prognostic factor for late recurrence and possibly predicted who could benefit most from extended hormonal treatment \[[@CR1]\]. However, these data were exploratory, and validation of their applicability to specific subgroups is needed. These multi-parameter assays are also limited by availability and cost. Clinicopathological parameters remain the key to clinical decision-making in our practice.

As for patterns of metastasis, patients who relapsed early tended to have liver and brain metastasis, whereas metastasis to the bone occurred independently of the period of time to relapse. For the course of disease, Fig. [2](#Fig2){ref-type="fig"} shows slower disease progression in the late group. These can be explained by more indolent biology in patients with late relapse.

The main limitation of our study was its retrospective design based on clinicopathological data. Some past adjuvant therapies also do not represent current standard practices; for instance, trastuzumab was rarely used in high-risk HER2^+^ breast cancer patients because of availability and reimbursement issues. In addition, some parameters such as Ki67 have not been used generally at the time of breast cancer diagnosis in our institution.

Conclusions {#Sec6}
===========

Larger and node-positive tumors associate with greater chances of early recurrence. Factors that predict late recurrence are luminal tumors, especially with concomitant PR-positive status, high ER titer, small tumor, negative lymph node, low grade, and HER2^−^ disease.

ER

:   Estrogen receptor

HER2

:   Human epidermal receptor 2

TN

:   Triple-negative

PR

:   Progesterone receptor

ICD10

:   International classification of disease and related health problem 10th revision

DFS

:   Disease-free survival
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